GlassScriptPhysician profile
Mark J Legome
NPI 1063505964
$1,326.02
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.87 · 2020: $177 · 2021: $734 · 2022: $402.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $425.58 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $186.48 | 2021-2022 | |
| Allergan, INC. | $155.97 | 2020 | |
| Biodelivery Sciences International, INC. | $76.42 | 2021 | |
| Redhill Biopharma INC. | $70.50 | 2021 | |
| Octapharma USA, INC. | $62.56 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.29 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $47.70 | 2021-2022 | |
| Grt US Holding, INC. | $45.00 | 2021 | |
| Alk-Abello, INC | $37.03 | 2021-2022 | |
| Abbvie INC. | $35.79 | 2021 | |
| Incyte Corporation | $25.46 | 2022 | |
| Jubilant Hollisterstier LLC | $24.21 | 2021 | |
| Biotissue Holdings INC. | $21.67 | 2022 | |
| Csl Behring | $21.43 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $18.06 | 2022 | |
| Fidia Pharma USA INC. | $12.87 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Legome listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.